包装 | 价格(元) |
5mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
Canonical SMILES | O=C([C@H](C(C1=CC=CC=C1)C2=CC=CC=C2)NC([C@H](CC3=CNC4=CC=CC=C34)NC([C@@H](NC([C@@H](NC([C@H](CC5=CNC6=CC=CC=C65)NC([C@H](CC7=CNC8=CC=CC=C78)NC([C@@H](NC([C@H](CCCCN)N)=O)CCCCN)=O)=O)=O)CCCCN)=O)CCCCN)=O)=O)N[C@@H](CCCCN)C(N)=O.OC(C(F)(F)F)=O |
分子式 | C78H106N18O9·XCF3COOH |
分子量 | 1439.8 |
溶解度 | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 1 mg/ml,PBS (pH 7.2): 10 mg/ml |
储存条件 | -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | LTX-315 is a synthetic cationic amphiphilic peptide.1It is cytotoxic to a variety of human cancer cell lines, including A20 lymphoma and AT-84 squamous cell carcinoma cells (IC50s = 8.3 and 11 µM, respectively), and to non-cancerous MRC-5 fibroblasts (IC50= 34.3 µM) but not human red blood cells (EC50= >695 µM).2LTX-315 is also cytotoxic to drug-sensitive and -resistant cancer cell lines (IC50s = 2.1-6.4 and 2.5-3.2 µM, respectively). It permeabilizes mitochondrial membranes and induces immunogenic cell death in tumor cellsin vitro.3,1Intratumoral administration of LTX-315 (1 mg peptide/50 µl saline) increases tumor levels of IL-1β and IL-6 and induces necrosis in, and complete regression of, tumors in a B16/F1 syngeneic mouse model of melanoma.4 1.Zhou, H., Forveille, S., Sauvat, A., et al.The oncolytic peptide LTX-315 triggers immunogenic cell deathCell Death Dis.7(3)e2134(2016) 2.Huag, B.E., Camilo, K.A., Eliassen, L.T., et al.Discovery of a 9-mer cationic peptide (LTX-315) as a potential first in class oncolytic peptideJ. Med. Chem.59(7)2918-2927(2016) 3.Zhou, H., Forveille, S., Sauvat, A., et al.The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilizationOncotarget6(29)26599-26614(2015) 4.Camilo, K.A., Berge, G., Ravuri, C.S., et al.Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315Cancer Immunol. Immunother.63(6)601-613(2014) |